{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:42:29Z","timestamp":1777704149706,"version":"3.51.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1370,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to the safety and efficacy of 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, and survival. The patients were randomized (1:1:2) to tacrolimus (TAC) and corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72), or MMF, TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146). In all, 295 HCV RNA\u2013positive subjects were enrolled. At 2 years, there were no differences in ACR, HCV recurrence (biochemical evidence), patient survival, or graft survival rates. The side effects of IS did not differ, although there was a trend toward less diabetes in the steroid-free group. Liver biopsy samples revealed no significant differences in the proportions of patients in arms 1, 2, and 3 with advanced HCV recurrence (ie, an inflammation grade \u2265 3 and\/or a fibrosis stage \u2265 2) in years 1 (48.2%, 50.4%, and 43.0%, respectively) and 2 (69.5%, 75.9%, and 68.1%, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS. Liver Transpl, 2011. \u00a9 2011 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.22417","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T18:49:53Z","timestamp":1313606993000},"page":"1394-1403","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":90,"title":["A Randomized, Multicenter Study Comparing Steroid-Free Immunosuppression and Standard Immunosuppression for Liver Transplant Recipients With Chronic Hepatitis C\u2020"],"prefix":"10.1097","volume":"17","author":[{"given":"G\u00f6ran B.","family":"Klintmalm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Teperman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Netto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Washburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Rudich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Pomfret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo E.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin","family":"Eckhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy L.","family":"Pruett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Heffron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Sher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhakar K.","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Kinkhabwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baburao","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Millis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda W.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos G.","family":"Fasola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20250124","doi-asserted-by":"crossref","first-page":"13981406","DOI":"10.1111\/j.1600-6143.2006.01256.x","article-title":"No improvement in longterm liver transplant graft survival in the last decade: an analysis of the UNOS data.","volume":"6","author":"Futagawa","year":"2006","journal-title":"Am J Transplant"},{"key":"R2-5-20250124","doi-asserted-by":"crossref","first-page":"889896","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation.","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"R3-5-20250124","doi-asserted-by":"crossref","first-page":"677684","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R4-5-20250124","doi-asserted-by":"crossref","first-page":"10331043","DOI":"10.1002\/hep.22448","article-title":"Improved outcomes in patients with hepatitis C with difficulttotreat characteristics: randomized study of higher doses of peginterferon alpha2a and ribavirin.","volume":"48","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"R5-5-20250124","doi-asserted-by":"crossref","first-page":"642650","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"issue":"pt 1","key":"R6-5-20250124","first-page":"852858","article-title":"Natural history of clinically compensated hepatitis C virusrelated graft cirrhosis after liver transplantation.","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"key":"R7-5-20250124","doi-asserted-by":"crossref","first-page":"553561","DOI":"10.1053\/jlts.2000.9741","article-title":"Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients.","volume":"6","author":"Testa","year":"2000","journal-title":"Liver Transpl"},{"key":"R8-5-20250124","doi-asserted-by":"crossref","first-page":"146152","DOI":"10.1097\/00075200-200306000-00003","article-title":"Impact of immunosuppression in hepatitis C recurrence after liver transplantation: a controllable factor?","volume":"8","author":"Fasola","year":"2003","journal-title":"Curr Opin Organ Transplant"},{"key":"R9-5-20250124","doi-asserted-by":"crossref","first-page":"884888","DOI":"10.1053\/jlts.2002.34640","article-title":"Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation.","volume":"8","author":"Brillanti","year":"2002","journal-title":"Liver Transpl"},{"key":"R10-5-20250124","doi-asserted-by":"crossref","first-page":"823830","DOI":"10.1002\/hep.510280333","article-title":"Predictors of patient and graft survival following liver transplantation for hepatitis C.","volume":"28","author":"Charlton","year":"1998","journal-title":"Hepatology"},{"key":"R11-5-20250124","doi-asserted-by":"crossref","first-page":"512525","DOI":"10.1002\/lt.21396","article-title":"Steroid avoidance in liver transplantation: metaanalysis and metaregression of randomized trials.","volume":"14","author":"Segev","year":"2008","journal-title":"Liver Transpl"},{"key":"R12-5-20250124","doi-asserted-by":"crossref","first-page":"585591","DOI":"10.1002\/lt.20631","article-title":"A novel threedose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study.","volume":"12","author":"Washburn","year":"2006","journal-title":"Liver Transpl"},{"key":"R13-5-20250124","doi-asserted-by":"crossref","first-page":"15211531","DOI":"10.1002\/lt.21182","article-title":"Corticosteroidfree immunosuppression with daclizumab in HCV liver transplant recipients: 1year interim results of the HCV3 study.","volume":"13","author":"Klintmalm","year":"2007","journal-title":"Liver Transpl"},{"key":"R14-5-20250124","doi-asserted-by":"crossref","first-page":"14091417","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis. An update on terminology and reporting.","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R15-5-20250124","first-page":"658663","article-title":"Banff schema for grading liver allograft rejection: an international consensus document.","volume":"25","year":"1997","journal-title":"Hepatology"},{"key":"R16-5-20250124","doi-asserted-by":"crossref","first-page":"11571162","DOI":"10.5858\/2006-130-1157-IAIHCG","article-title":"Colby TV, dePetris G, Sharkey FE, et al.; for Hepatitis C, 3 Trial Group. Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the Hepatitis C 3 multiinstitutional trial experience.","volume":"130","author":"Netto","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"R17-5-20250124","doi-asserted-by":"crossref","first-page":"465472","DOI":"10.1111\/j.1365-2893.2005.00615.x","article-title":"Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.","volume":"12","author":"Terrault","year":"2005","journal-title":"J Viral Hepat"},{"key":"R18-5-20250124","doi-asserted-by":"crossref","first-page":"457481","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R19-5-20250124","first-page":"163170","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration.","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"R20-5-20250124","doi-asserted-by":"crossref","first-page":"384393","DOI":"10.1097\/00000658-200109000-00012","article-title":"A 10year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients.","volume":"234","author":"Ghobrial","year":"2001","journal-title":"Ann Surg"},{"key":"R21-5-20250124","doi-asserted-by":"crossref","first-page":"14961503","DOI":"10.1002\/lt.20849","article-title":"Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV allografts.","volume":"12","author":"Khapra","year":"2006","journal-title":"Liver Transpl"},{"key":"R22-5-20250124","doi-asserted-by":"crossref","first-page":"11331138","DOI":"10.1111\/j.1600-6143.2004.00470.x","article-title":"Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C.","volume":"4","author":"Russo","year":"2004","journal-title":"Am J Transplant"},{"key":"R23-5-20250124","first-page":"475480","article-title":"HCV antibody quantitative levels in liver transplant patients: do they have any relevance in clinical practice?","volume":"4","author":"Jain","year":"2006","journal-title":"Exp Clin Transplant"},{"key":"R24-5-20250124","doi-asserted-by":"crossref","first-page":"811816","DOI":"10.1111\/j.1478-3231.2006.01301.x","article-title":"Antiviral treatment withdrawal in viremic HCVpositive liver transplant patients: impact on viral loads, allograft function and morphology.","volume":"26","author":"Kornberg","year":"2006","journal-title":"Liver Int"},{"key":"R25-5-20250124","doi-asserted-by":"crossref","first-page":"130135","DOI":"10.1002\/lt.21037","article-title":"Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation.","volume":"13","author":"Nebbia","year":"2007","journal-title":"Liver Transpl"},{"issue":"suppl 1","key":"R26-5-20250124","first-page":"S107S114","article-title":"Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases liver transplantation database.","volume":"5","author":"Charlton","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"R27-5-20250124","doi-asserted-by":"crossref","first-page":"493499","DOI":"10.1097\/00007890-199808270-00014","article-title":"A longterm comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group.","volume":"66","author":"Wiesner","year":"1998","journal-title":"Transplantation"},{"key":"R28-5-20250124","doi-asserted-by":"crossref","first-page":"762767","DOI":"10.1002\/lt.20655","article-title":"Effect of calcineurin inhibitors on survival and histologic disease severity in HCVinfected liver transplant recipients.","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"R29-5-20250124","doi-asserted-by":"crossref","first-page":"442450","DOI":"10.1053\/jlts.2001.23356","article-title":"A randomized doubleblind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transpl"},{"key":"R30-5-20250124","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1053\/jlts.2003.50003","article-title":"Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection.","volume":"9","author":"Firpi","year":"2003","journal-title":"Liver Transpl"},{"key":"R31-5-20250124","doi-asserted-by":"crossref","first-page":"892905","DOI":"10.1111\/j.1432-2277.2009.00893.x","article-title":"Corticosteroidfree immunosuppression in liver transplantation: a metaanalysis and metaregression of outcomes.","volume":"22","author":"Sgourakis","year":"2009","journal-title":"Transpl Int"},{"key":"R32-5-20250124","doi-asserted-by":"crossref","first-page":"439447","DOI":"10.1196\/annals.1423.046","article-title":"Impact of steroids on hepatitis C virus replication in vivo and in vitro.","volume":"1110","author":"Henry","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"R33-5-20250124","doi-asserted-by":"crossref","first-page":"198200","DOI":"10.1038\/nrgastro.2009.38","article-title":"Transplantation: steroid use in HCVinfected liver transplant recipients.","volume":"6","author":"Roche","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R34-5-20250124","doi-asserted-by":"crossref","first-page":"17521760","DOI":"10.1002\/lt.21629","article-title":"; for THOSIN Study Group. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study.","volume":"14","author":"Llado","year":"2008","journal-title":"Liver Transpl"},{"key":"R35-5-20250124","doi-asserted-by":"crossref","first-page":"829835","DOI":"10.1097\/01.tp.0000282914.20578.7b","article-title":"Randomized trial of steroidfree induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.","volume":"84","author":"Kato","year":"2007","journal-title":"Transplantation"},{"key":"R36-5-20250124","doi-asserted-by":"crossref","first-page":"12141216","DOI":"10.1016\/j.transproceed.2004.12.153","article-title":"Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation.","volume":"37","author":"Pelletier","year":"2005","journal-title":"Transplant Proc"},{"key":"R37-5-20250124","doi-asserted-by":"crossref","first-page":"587591","DOI":"10.1097\/01.tp.0000279003.40279.0e","article-title":"Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation.","volume":"84","author":"Cotler","year":"2007","journal-title":"Transplantation"},{"key":"R38-5-20250124","doi-asserted-by":"crossref","first-page":"24082414","DOI":"10.1111\/j.1572-0241.2002.05995.x","article-title":"Contribution of obesity to hepatitis Crelated fibrosis progression.","volume":"97","author":"Ortiz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R39-5-20250124","doi-asserted-by":"crossref","first-page":"15771585","DOI":"10.1053\/j.gastro.2010.07.058","article-title":"Variants in IL28B in liver recipients and donors correlate with response to peginterferon and ribavirin therapy for recurrent hepatitis C.","volume":"139","author":"Fukuhara","year":"2010","journal-title":"Gastroenterology"},{"key":"R40-5-20250124","doi-asserted-by":"crossref","first-page":"317324","DOI":"10.1002\/hep.24074","article-title":"Interleukin28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.","volume":"53","author":"Charlton","year":"2011","journal-title":"Hepatology"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22417","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201112000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:09:29Z","timestamp":1737738569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201112000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22417","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}